Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma

Completed

• Conditions: Adenocarcinoma; Esophageal Cancer

• Registration Number: NCT01824966
• Lead Sponsor: University Hospital, Gasthuisberg

Brief Summary

There has been much controversy surrounding the biologic behavior and prognosis of esophageal signet ring cell (SRCs) containing carcinomas. To clarify the biologic behavior of SRCs, the investigators compared the clinicopathologic features and prognosis of SRCs with other adenocarcinomas (ADC) of the esophagus and gastroesophageal junction (GEJ).

Detailed Description

Adenocarcinoma (ADC) of the esophagus and gastroesophageal junction (GEJ) is an aggressive neoplasm and has a poor prognosis. Surgical based treatment has been the treatment of choice for localized esophageal adenocarcinoma.

Signet-ring cell carcinoma is a unique histologic subtype of adenocarcinoma characterized by abundant intracellular mucin accumulation and a compressed nucleus displaced toward one extremity of the cell (the so-called signet-ring cell (SRC)). According to the World Health Organisation (WHO), a true signet-ring cell carcinoma (SRCca) is defined as an adenocarcinoma in which the predominant component (more than 50% of the tumor) consists of isolated or small groups of SRC in the stroma. If the tumor contains less than 50% of those cells, it is generally considered as an adenocarcinoma (ADC).

Study Timeline

• Study Start: 2012-03
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Status Verified: 2013-04
• Study First Submitted: 2013-04-02
• Study First Submitted QC: 2013-04-04
• Last Update Submitted: 2013-04-04
• Study First Posted: 2013-04-05
• Last Update Posted: 2013-04-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

• Adenocarcinoma R0 resection Primary surgery

Exclusion Criteria

• Other histology R1 or R2 resection Neoadjuvant therapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cancer specific 5 year survival in SRCC	from surgery	Cancer specific 5 year survival classified into two groups according to WHO criteria (\>50% SRC or \<50% SRC)

Trial Locations

Locations (1)

University Hospital Leuven; Dept. of Thoracic Surgery; 🇧🇪 Leuven, Belgium